Principal Financial Group Inc. Has $4.80 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Principal Financial Group Inc. boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 740.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 86,440 shares of the biopharmaceutical company's stock after purchasing an additional 76,150 shares during the period. Principal Financial Group Inc. owned approximately 0.09% of Ultragenyx Pharmaceutical worth $4,802,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RARE. Wilmington Savings Fund Society FSB bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $83,000. Geode Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 4.4% during the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock valued at $87,296,000 after purchasing an additional 65,623 shares during the last quarter. M&T Bank Corp lifted its stake in Ultragenyx Pharmaceutical by 8.1% during the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock valued at $388,000 after purchasing an additional 525 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Ultragenyx Pharmaceutical by 49.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 633,715 shares of the biopharmaceutical company's stock worth $35,203,000 after buying an additional 208,715 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new position in Ultragenyx Pharmaceutical in the third quarter worth approximately $93,000. 97.67% of the stock is owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the business's stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company's stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 8,273 shares of the company's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the sale, the chief executive officer now owns 2,195,712 shares of the company's stock, valued at approximately $109,785,600. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,465 shares of company stock valued at $1,302,735. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Up 0.9 %

Shares of NASDAQ:RARE traded up $0.35 during trading on Friday, reaching $41.50. 1,482,758 shares of the company traded hands, compared to its average volume of 1,509,129. The firm has a fifty day simple moving average of $46.95 and a 200 day simple moving average of $49.33. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm has a market cap of $3.83 billion, a P/E ratio of -6.41 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same quarter in the previous year, the company posted ($2.23) earnings per share. The business's quarterly revenue was up 42.3% compared to the same quarter last year. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current year.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of recent research reports. TD Cowen increased their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. HC Wainwright reissued a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $88.46.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.